Patents by Inventor Jeffrey Schlom

Jeffrey Schlom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination immunotherapy compositions against cancer and methods
    Patent number: 10874729
    Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: December 29, 2020
    Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept of Health and Human Services
    Inventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
  • BRACHYURY DELETION MUTANTS, NON-YEAST VECTORS ENCODING BRACHYURY DELETION MUTANTS, AND THEIR USE
    Publication number: 20200181215
    Abstract: The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.
    Type: Application
    Filed: January 31, 2020
    Publication date: June 11, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • IMMUNOGENIC MODULATION BY ENDOCRINE DEPRIVATION THERAPY IMPROVES SENSITIVITY OF TUMOR CELLS TO IMMUNE MEDIATED LYSIS
    Publication number: 20200140567
    Abstract: The invention is directed to methods of reducing growth of prostate cancer cells and breast cancer cells, which comprises treating such cancer cells with a combination of androgen or endocrine deprivation therapy (e.g., enzalutamide, abiraterone, and tamoxifen) and immunotherapy.
    Type: Application
    Filed: November 18, 2019
    Publication date: May 7, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Jeffrey Schlom, James W. Hodge
  • HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE
    Publication number: 20200109181
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 9, 2020
    Applicant: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • Combination Immunotherapy Compositions Against Cancer and Methods
    Publication number: 20200069784
    Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.
    Type: Application
    Filed: July 1, 2019
    Publication date: March 5, 2020
    Inventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
  • YEAST-BASED IMMUNOTHERAPY FOR CHORDOMA
    Publication number: 20200046818
    Abstract: Disclosed are methods of the treatment or prevention of chordoma which include the step of administering a yeast-based immunotherapeutic composition. The yeast-based immunotherapeutic composition preferably comprises a Brachyury antigen.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 13, 2020
    Inventors: Timothy C. RODELL, David APELIAN, Claudia PALENA, Jeffrey SCHLOM
  • deletion mutants, non-yeast vectors encoding deletion mutants, and their use
    Patent number: 10550164
    Abstract: The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: February 4, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • Yeast-based immunotherapy for Chordoma
    Patent number: 10507235
    Abstract: One embodiment of the invention relates to a method to treat chordoma in an individual who has chordoma. The method includes the step of administering to an individual who has chordoma, an immunotherapeutic composition comprising: (a) a yeast vehicle; and (b) a cancer antigen comprising at least one Brachyury antigen. Another embodiment of the invention relates to the use of an immunotherapeutic composition comprising a yeast vehicle and a cancer antigen comprising at least one Brachyury antigen to chordoma in an individual who has chordoma. Yet another embodiment of the invention relates to the use an immunotherapeutic composition comprising a yeast vehicle.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: December 17, 2019
    Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Timothy C. Rodell, David Apelian, Claudia Palena, Jeffrey Schlom
  • Nucleic acids encoding HLA-A24 agonist epitopes of MUC1-C oncoprotein
    Patent number: 10508141
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: December 17, 2019
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • YEAST-BRACHYURY IMMUNOTHERAPEUTIC COMPOSITIONS
    Publication number: 20190374624
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
    Type: Application
    Filed: April 19, 2019
    Publication date: December 12, 2019
    Inventors: Claudia Palena, Zhimin Guo, David Apelian, Jeffrey Schlom
  • DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS
    Publication number: 20190314479
    Abstract: The invention provides HPV agonist epitopes, which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of HPV infection and/or cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.
    Type: Application
    Filed: November 6, 2017
    Publication date: October 17, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • Combination immunotherapy compositions against cancer and methods
    Patent number: 10383924
    Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: August 20, 2019
    Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
  • YEAST-MUC1 IMMUNOTHERAPEUTIC COMPOSITIONS AND USES THEREOF
    Publication number: 20190231859
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).
    Type: Application
    Filed: December 6, 2018
    Publication date: August 1, 2019
    Inventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang
  • Yeast-brachyury immunotherapeutic compositions
    Patent number: 10363294
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: July 30, 2019
    Assignees: GlobeImmune, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Claudia Palena, Zhimin Guo, David Apelian, Jeffrey Schlom
  • BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE
    Publication number: 20190046619
    Abstract: Brachyury protein can be used to induce Brachyury-specific CD4+ T cells in vivo and ex vivo. It is also disclosed that Brachyury protein can be used to stimulate the production of both Brachyury-specific CD4+ T cells and Brachyury-specific CD8+ T cells in a subject, such as a subject with cancer. In some embodiments, the methods include the administration of a Brachyury protein. In additional embodiments, the methods include the administration of a nucleic acid encoding the Brachyury protein, such as in a non-pox non-yeast vector. In further embodiments, the method include the administration of host cells expressing the Brachyury protein.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 14, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • Yeast-MUC1 immunotherapeutic compositions and uses thereof
    Patent number: 10188714
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 29, 2019
    Assignees: GlobeImmune, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang
  • HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE
    Publication number: 20190002513
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Application
    Filed: July 13, 2018
    Publication date: January 3, 2019
    Applicant: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • Native and agonist CTL epitopes of the MUC1 tumor antigen
    Patent number: 10138271
    Abstract: The invention provides peptides comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) mucin 1 (MUC1) and analogs thereof, which can be used in vaccine prevention or therapy of cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: November 27, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • BRACHYURY DELETION MUTANTS, NON-YEAST VECTORS ENCODING BRACHYURY DELETION MUTANTS, AND THEIR USE
    Publication number: 20180222951
    Abstract: The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.
    Type: Application
    Filed: August 3, 2016
    Publication date: August 9, 2018
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • MODIFIED YEAST-BRACHYURY IMMUNOTHERAPEUTIC COMPOSITIONS
    Publication number: 20180214525
    Abstract: Disclosed are improved yeast-based immunotherapeutic compositions comprising modified Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
    Type: Application
    Filed: August 1, 2016
    Publication date: August 2, 2018
    Inventors: Thomas H. KING, Zhimin GUO, Jeffrey SCHLOM, Claudia PALENA